Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer

The 21-gene recurrence score (RS) assay, also known as Oncotype DX, is an important genetic tool that measures 21 genes in tumor samples. From this, a patient's recurrence score can be calculated, providing insights into the likelihood of distant recurrence and predictive data on chemotherapy benefits. Stage T3N0 disease, defined by large tumors without lymph node involvement, poses distinct clinical challenges, with the optimal management approach still under discussion. Consequently, the implications of RS testing in guiding chemotherapy choice and its impact on survival outcomes for T3N0 luminal breast cancer remain less clearly defined. This study seeks to explore these critical...